

For FILSPARI® (sparsentan) prescribers



Start Here for FILSPARI (sparsentan) Prior Authorizations

96% of commercially insured patients have access to FILSPARI, and a prior authorization (PA) is likely required

Gather the following clinical information when you're ready to submit the PA:

- Individual is 18 years or older
- Diagnosis of primary IgAN (kidney biopsy, if available)
- Prior use or intolerance of corticosteroid
- Proteinuria (g/g or g/day) and eGFR
- History of failure of an **ACEi/ARB** or trial for 3 months. Some examples of ACEi/ARB:
 - **ACEis tend to end in "-pril"**: benazepril, enalapril, lisinopril¹
 - **ARBs tend to end in "-tan"**: losartan, irbesartan, valsartan²

What you can expect with the PA process:

A PA means that your office **must submit clinical information** before FILSPARI is approved for your patient.

- Your office can **submit a PA electronically** through the Traverse TotalCare® electronic PA (ePA) system, or fax it to the insurance plan
- The insurance plan will review the PA and **make a coverage decision**
- If a PA is denied, which may be due to missing required information, your Traverse Access & Reimbursement Manager can help avoid an additional delay in treatment

Two PAs may be required for 200 mg initiation and 400 mg maintenance dosing

Visit [TraverseTotalCare.com](https://www.TraverseTotalCare.com) for more information and downloadable access resources.

ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; eGFR, estimated glomerular filtration rate; IgAN, immunoglobulin A nephropathy.

The Traverre TotalCare® ePA process



Complete the FILSPARI Patient Start Form. To receive the ePA login information, include the email address and/or fax number for your office staff who handle PA support.



A patient-specific PIN for the login to the ePA system will be sent to your staff member via email and/or fax.



Using the PIN, complete and submit the ePA, including required documentation, in the portal.

Have all documentation on hand when you are ready to submit. The Traverre TotalCare® ePA system will guide you through questions and the documentation upload.

Reach out to your Access & Reimbursement Manager when you're ready to start your ePA submission for support

You can count on Traverre TotalCare® for assistance with coordinating patient access to treatment with FILSPARI® (sparsentan).

Call **1-833-345-7727**, Monday-Friday 8 AM-8 PM ET or visit us online.

ePA, electronic prior authorization; PA, prior authorization.

References: 1. Mayo Clinic. Angiotensin-converting enzyme (ACE) inhibitors. Updated August 16, 2023. Accessed October 8, 2024. <https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/ace-inhibitors/art-20047480> 2. Mayo Clinic. Angiotensin II receptor blockers. Updated August 4, 2023. Accessed October 8, 2024. <https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/angiotensin-ii-receptor-blockers/art-20045009>